ID | 69045 |
FullText URL | |
Author |
Uka, Mayu
Department of Radiology, Okayama University Hospital
Iguchi, Toshihiro
Department of Radiology, Okayama University Hospital
Kaken ID
Bekku, Kensuke
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Yamanoi, Tomoaki
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Mitsuhashi, Toshiharu
Center for Innovative Clinical Medicine, Okayama University Hospital
Kaken ID
researchmap
Gobara, Hideo
Division of Medical Informatics, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
Umakoshi, Noriyuki
Department of Radiology, Okayama University Hospital
Kawabata, Takahiro
Department of Radiology, Okayama University Hospital
Tomita, Koji
Department of Radiology, Okayama University Hospital
Matsui, Yusuke
Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Araki, Motoo
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Hiraki, Takao
Department of Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
|
Abstract | Background: No direct cost comparison has been conducted between percutaneous cryoablation (PCA) and robot-assisted partial nephrectomy (RAPN) for clinical T1a renal cell carcinoma (RCC) in Japan. This study aimed to compare their costs.
Methods: We retrospectively analyzed data from 212 PCAs (including 155 with transcatheter arterial embolization) and 119 RAPN cases performed between December 2017 and May 2022. Results: PCA patients were older with higher American Society of Anesthesiologists scores, Charlson Comorbidity Index, and history of previous RCC treatment, cardiovascular disease, and antithrombotic drug use than RAPN patients. PCA was associated with a significantly shorter procedure time and hospitalization duration with fewer major complications than those associated with RAPN. While PCA incurred a slightly lower total cost (1,123,000 vs. 1,155,000 yen), it had a significantly higher procedural cost (739,000 vs. 693,000 yen) and markedly worse total (− 93,000 vs. 249,000 yen) and procedural income-expenditure balance (− 189,000 vs. 231,000 yen) than those of RAPN. After statistical adjustment, PCA demonstrated significantly higher total (difference: 114,000 yen) and procedural costs (difference: 72,000 yen), alongside significantly worse total (difference: − 358,000 yen) and procedural income-expenditure balances (difference: − 439,000 yen). The incremental cost-effectiveness ratio was more favorable for PCA than for RAPN. Conclusion: For high- risk patients, PCA demonstrated a safer option with shorter hospitalization duration than those of RAPN. Although PCA was more cost-effective, its higher procedural cost and unfavorable income-expenditure balance require careful evaluation, especially for large tumors that require three or more needles. |
Keywords | Renal cancer
Cryoablation
Robot-assisted partial nephrectomy
Cost
Cost effectiveness
|
Note | The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s10147-025-02783-5
|
Published Date | 2025-06-06
|
Publication Title |
International Journal of Clinical Oncology
|
Volume | volume30
|
Issue | issue8
|
Publisher | Springer Science and Business Media LLC
|
Start Page | 1621
|
End Page | 1630
|
ISSN | 1341-9625
|
NCID | AA11086579
|
Content Type |
Journal Article
|
language |
English
|
OAI-PMH Set |
岡山大学
|
Copyright Holders | © The Author(s) 2025
|
File Version | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
Related Url | isVersionOf https://doi.org/10.1007/s10147-025-02783-5
|
License | http://creativecommons.org/licenses/by/4.0/
|
Citation | Uka, M., Iguchi, T., Bekku, K. et al. Percutaneous cryoablation versus robot-assisted partial nephrectomy for small renal cell carcinoma: a retrospective cost analysis at Japanese single-institution. Int J Clin Oncol 30, 1621–1630 (2025). https://doi.org/10.1007/s10147-025-02783-5
|
助成情報 |
( 国立大学法人岡山大学 / Okayama University )
|